Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review

@article{Knight2009MycophenolateMD,
  title={Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review},
  author={S. Knight and N. Russell and L. Barcena and P. Morris},
  journal={Transplantation},
  year={2009},
  volume={87},
  pages={785-794}
}
Background. Mycophenolate mofetil (MMF) has increasingly replaced azathioprine (AZA) as the antimetabolite of choice in immunosuppressive protocols. Initial trials comparing MMF with AZA in patients receiving cyclosporine A sandimmune showed a clinical benefit in reducing the incidence of acute rejections. It has been questioned whether this benefit remains significant when using newer formulations of cyclosporine A (neoral) and tacrolimus. Methods. Literature searches were performed using the… Expand
View on Wolters Kluwer
ncbi.nlm.nih.gov
143 Citations
Highly Influential Citations
6
Background Citations
48
Methods Citations
3
Results Citations
12

143 Citations

Citation Type

Citation Type

Mycophenolate Versus Azathioprine for Kidney Transplantation: A 15-Year Follow-Up of a Randomized Trial
TLDR
This long-term examination of the Australian cohort of patients enrolled in this study using follow-up data from the Australia and New Zealand Dialysis and Transplant Registry found little evidence for the superiority of MMF over AZA. Expand
Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial
TLDR
It is found that in deceased donor kidney transplant recipients on low-dose CsA and no steroids, MMF had no significant benefits over AZA, suggesting thatAZA, due to its lower costs, could safely replace MMF in combination with minimized immunosuppression. Expand
Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.
  • O. Raheem, P. Daly, +7 authors D. Hickey
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
There was no difference in acute rejection episodes between MMF and AZA based immunotherapy and there was no significant difference concerning graft survival in the MMF group when compared to AZA group. Expand
Long-term outcome of azathioprine versus mycophenolate mofetil in cyclosporine-based immunosuppression in kidney transplantation: 10 years of experience at a single center.
TLDR
Compared with AZA, MMF offered the clinical benefit of prevention of acute rejection episodes, but displayed similar effects on long-term graft and patient survivals in kidney transplant recipients undergoing cyclosporine-based immunosuppression. Expand
mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
TLDR
mTOR-I showed no particular superiority to MPA, and had an increased risk of graft loss when combined with CNI, even when Combined with a reduced dose of CNI. Expand
Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programme
TLDR
In tacrolimus-based Immunosuppression, azathioprine may be as good as MMF as maintenance immunosuppressive drug in living donor kidney transplantation and it is also a more cost-effective immunOSuppression. Expand
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
TLDR
This review of randomised controlled trials (RCTs) aimed to look at the benefits and harms of MPA versus AZA in primary immunosuppressive regimens after kidney transplantation, including their efficacy for maintaining graft and patient survival, prevention of acute rejection, maintaining graft function and their safety, including infections, malignancies and other adverse events. Expand
Mycophenolate Mofetil Use Is Associated With Prolonged Graft Survival After Kidney Transplantation
TLDR
The data from this observational study suggest that mycophenolate mofetil use was associated with a lower risk of graft loss than azathioprine-based immunosuppression. Expand
Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients
TLDR
The results show the safety profile of MMF in pediatric renal transplant patients and can be used to update information used for prescriptions for pediatric patients. Expand
Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis.
TLDR
MZR is an effective and safe immunosuppressive agent and high-dose MZR can be recommended as an alternative to MMF following adult renal transplantation in Asia, but hyperuricemia and liver damage should be closely monitored during the medication period. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial
TLDR
In recipients of cadaver kidney-transplants given ciclosporin microemulsion, mycophenolate mofetil offers no advantages over azathioprine in preventing acute rejections and is about 15 times more expensive. Expand
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
TLDR
In renal transplant recipients who were on immunosuppressive therapy with the cyclosporine microemulsion Neoral, mycophenolate mofetil (MMF) was not better than azathioprine in preventing acute rejection at 21 mo after transplantation and was 15 times more expensive. Expand
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
TLDR
MMF is associated with a significantly lower rate of treatment failure compared with AZA during the first 6 months after renal transplantation and produces a clinically important reduction in the incidence, severity, and treatment of acute graft rejection. Expand
Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
TLDR
All regimens yielded similar acute rejection rates and graft survival, but the tacrolimus + MMF regimen was associated with the lowest rate of steroid resistant rejection requiring antilymphocyte therapy. Expand
Efficacy of mycophenolate mofetil versus azathioprine after renal transplantation: a systematic review.
TLDR
Compared with AZA, MMF is a more potent immunosuppressive drug, that is more efficient in reducing the incidence of acute rejection episodes after renal transplantation. Expand
Safety And Efficacy Of Tacrolimus In Combination With Mycophenolate Mofetil (mmf) In Cadaveric Renal Transplant Recipients1
TLDR
Tacrolimus in combination with an initial dose of Mycophenolate mofetil 2 g/day is a very effective and safe regimen in cadaveric kidney transplant recipients. Expand
Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
TLDR
MMF proved superior to AZA as a posttransplant immunosuppressant in conjunction with cyclosporine and corticosteroids and performed consistently better for both MMF treatment groups at 3, 6, and 12 months. Expand
Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
TLDR
Tacrolimus in combination with an initial dose of MMF 2 g/day is a very effective and safe regimen in cadaveric kidney transplant recipients. Expand
Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study1
TLDR
Replacement of MMF by AZA after 3 months of therapy with ME-CsA and steroids provides comparable efficacy and safety profiles to continuous MMF over 12 months. Expand
Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review.
TLDR
The use of MMF is associated with slight increases in gastrointestinal adverse effects, some hematologic adverse events, and CMV infections compared with Aza, and larger sample sizes of randomized controlled trials are needed. Expand
...
1
2
3
4
5
...